Trials / Conditions / Malignant Solid Tumour

Malignant Solid Tumour

26 registered clinical trials studyying Malignant Solid Tumour — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endo NCT07044336	AstraZeneca	Phase 3
Completed	Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid T NCT02923466	Vyriad, Inc.	Phase 1
Completed	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors NCT02857920	Fuda Cancer Hospital, Guangzhou	Phase 1 / Phase 2
Completed	Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors NCT02853903	Fuda Cancer Hospital, Guangzhou	Phase 2
Completed	Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors NCT02843204	Fuda Cancer Hospital, Guangzhou	Phase 1 / Phase 2
Completed	Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generati NCT02786628	UNC Lineberger Comprehensive Cancer Center	—
Completed	A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours NCT01721148	ASLAN Pharmaceuticals	Phase 1
Completed	Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated NCT01611857	SCRI Development Innovations, LLC	Phase 1 / Phase 2
Completed	ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers NCT01598129	Targovax Oy	Phase 1
Completed	Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies NCT01554371	University of California, San Francisco	Phase 1 / Phase 2
Completed	An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Ag NCT01618136	Eisai Limited	Phase 1 / Phase 2
Completed	Vaccine Therapy in Treating Patients With Metastatic Solid Tumors NCT01376505	Robert Wesolowski	Phase 1
Completed	A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors NCT01325558	Altor BioScience	Phase 1
Completed	Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advan NCT01286896	The Netherlands Cancer Institute	Phase 1
Completed	Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors NCT01337505	ImmunityBio, Inc.	Phase 1
Completed	Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors NCT01343498	SCRI Development Innovations, LLC	Phase 1
Completed	Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors NCT01184807	Otsuka Beijing Research Institute	Phase 1
Completed	Hydroxychloroquine + Vorinostat in Advanced Solid Tumors NCT01023737	The University of Texas Health Science Center at San Antonio	Phase 1
Completed	A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver NCT00969410	AVEO Pharmaceuticals, Inc.	Phase 1
Terminated	Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer NCT00801151	Institut Claudius Regaud	Phase 1
Completed	Phase I Study of Vorinostat and Sorafenib in Advanced Cancer NCT00635791	University of Colorado, Denver	Phase 1
Completed	Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors NCT00551096	University of Colorado, Denver	Phase 1
Completed	Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies NCT00388427	University of Pittsburgh	Phase 1
Completed	BN80927 in Patients With Advanced Malignant Solid Tumors NCT01435096	Ipsen	Phase 1
Completed	To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours NCT01951846	Boehringer Ingelheim	Phase 1
No Longer Available	Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 NCT01151930	SynCore Biotechnology Co., Ltd.	—